Latest Articles
Unravelling Multilayered RNA Modification Networks in Female Reproduction and Obstetric/Gynaecologic Disorders.
Background/Objective: RNA modifications, including N6-methyladenosine (m6A), 5-methylcytosine (m5C), 7-methylguanosine (m7G), N1-methyladenosine (m1A), pseudouridine (Ψ), N4-acetylcytidine (ac4C), 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) and adenosine-to-inosine (A-to-I) editing, constitute a critical layer of post-transcriptional regulation that …
Published: April 13, 2026, midnight
Data From the CARE Trial in Recurrent/Advanced Endometrial Cancer - OncLive
Data From the CARE Trial in Recurrent/Advanced Endometrial Cancer OncLive
Published: April 12, 2026, 9:28 p.m.
Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer - OncLive
Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer OncLive
Published: April 12, 2026, 9:01 p.m.
Dr Pothuri on Preliminary Data With Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer - OncLive
Dr Pothuri on Preliminary Data With Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer OncLive
Published: April 12, 2026, 9 p.m.
Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug - MedPage Today
Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug MedPage Today
Published: April 12, 2026, 8:01 p.m.
A Look At BioNTech (BNTX) Valuation After Positive Phase 2 HER2 Endometrial Cancer Data - simplywall.st
A Look At BioNTech (BNTX) Valuation After Positive Phase 2 HER2 Endometrial Cancer Data simplywall.st
Published: April 12, 2026, 7:29 p.m.
Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer - OncLive
Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer OncLive
Published: April 12, 2026, 6:25 p.m.
Peer Support Helps Black Women With Endometrial Cancer Stay on Treatment - Cure Today
Peer Support Helps Black Women With Endometrial Cancer Stay on Treatment Cure Today
Published: April 12, 2026, 6:04 p.m.
BioNTech's Endometrial Cancer Data Signals Pivotal Pipeline Progress - AD HOC NEWS
BioNTech's Endometrial Cancer Data Signals Pivotal Pipeline Progress AD HOC NEWS
Published: April 12, 2026, 5:41 p.m.
Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer - OncLive
Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer OncLive
Published: April 12, 2026, 2:35 p.m.
Link copied to clipboard!